Exelixis is an SME based in Athens, Greece. We provide consultancy and a wide range of management services in the field of Research and Technological Development.
Our clients are Researchers coming both from the public and private sector (Universities, Research Institutes, private RTD companies) from across Europe.
Regardless of your research topic we actively support you to transform your idea into a competitive proposal and when your proposal is funded, we completely undertake the day-to-day management activities of your project and support you in the effective communication and exploitation of your project results.
A member of our PR team
will undertake the organization of the internal meetings (kick-off and progress meetings) and be in charge of dissemination activities (project web site, press releases, document distribution).
An experienced accountant will be responsible for the budget monitoring in terms of the eligibility of the costs charged to the project and in charge of drafting the interim and final financial reports of the consortium and subsequently responsible for the close monitoring of any obligations of financial nature that arise from the Grant Agreement and annexes
A procurement specialist will assist the PI and other partners of the consortium in the procurement procedures that have to be followed during the implementation of the project, according to EC legislation.
Exelixis also cooperates with very experienced IPR advisors who will provide to the consortium ad hoc legal advice throughout the duration of the project for any IPR issues that might arise from the development of the project.
ONGOING EU PROJECTS
HARMONIzation and integrative analysis of regional, national and international Cohorts on primary Sjögren’s Syndrome (pSS) towards improved stratification, treatment and health policy making.
HarmonicSS. - No of Partners: 35
1/1/2017 - 30/06/2020
The CURE project
(full title “Constructing a ‘Eubiosis Reinstatement Therapy’ for Asthma” is proposing a phage therapy that could control the immune dysregulation of the disease and may eventually be able to cure it. CURE receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 767015.
Duration: 1/10/2017 - 30/09/2021